The genetics of spinocerebellar ataxia and dystonia by Nibbeling, Esther
  
 University of Groningen
The genetics of spinocerebellar ataxia and dystonia
Nibbeling, Esther
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Nibbeling, E. (2017). The genetics of spinocerebellar ataxia and dystonia. [Groningen]: Rijksuniversiteit
Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
4
Genetic screening of glutamatergic 
components in cases suspected to 
suffer from cerebellar ataxia reveals a 
link with intellectual disability
C.J.L.M. Smeets1,*, E.A.R. Nibbeling1,*, M.R. Fokkens1, D. Brandenburg-Weening1, F. Yi2, 
K. N. Dorsett2, G.C. Bullard2, G. van der Vries1, C.C. Verschuuren-Bemelmans1, 
K.B. Hansen2, R.J. Sinke1, and D.S. Verbeek1 
 
 
1. Department of Genetics, University Medical Centre Groningen,  
University of Groningen, Groningen, the Netherlands
2. Department of Biomedical & Pharmaceutical Sciences,  
University of Montana, Missoula, Montana,  
United States of America
* These authors contributed equally
Manuscript in preparation





Spinocerebellar ataxia (SCA) represents a group of complex heterogeneous neuro-
degenerative disorders that cause cerebellar atrophy leading to ataxia.1 Despite the fact 
that more than 40 genes have been identified as causing SCA,2 approximately 30% of 
cases remain genetically undiagnosed. The different SCA genes have diverse functions, 
but operate in shared biological pathways, including synaptic transmission.3,4 
Glutamate signaling controls proper neurotransmission and alterations have been 
associated with diverse neurological diseases including intellectual disability, and au-
tism.5 Mutations in the ionotropic glutamate receptor GluD2 (GRID2) and metabotropic 
glutamate receptor 1 have been reported to cause congenital cerebellar ataxia and 
adult-onset spinocerebellar ataxia,6,7 and autosomal-recessive congenital cerebellar 
ataxia 8, respectively. Additionally, mutations in the glutamate transporter EAAT1 cause 
episodic ataxia, hemiplegia and ataxia.9 
To determine whether alterations in glutamate signaling are a common theme under-
lying cerebellar ataxia, we screened a randomly selected cohort of 96 Dutch patients 
suspected to suffer from cerebellar ataxia but without mutations in the SCA1-3, 6, 7, 17, 
19 and 23 genes, for mutations in 39 genes involved in glutamatergic signaling using 
targeted re-sequencing (for details see Supplementary Table 1). This study has been 
approved by the local ethics committee. 
We identified a novel truncating variation, c.2415C>A, p.Cys805*, in glutamate receptor 
GluA3 (GRIA3) in a male patient, whom from two and a half years on, suffered from 
intellectual and motor disabilities. To date, only four truncating variations in GRIA3 are 
reported in the ExAC browser, of which three are very rare (MAF <0.00001), suggest-
ing that truncating variations in GRIA3 are not well tolerated. Mutations in GRIA3 have 
previously been reported to cause X-linked intellectual disability in humans.5 Therefore, 
we consider this p.Cys805* variant pathogenic and the boy should be diagnosed with 
X-linked intellectual disability. 
Next, we identified a novel truncating variant, c.2523delA, p.Glu841fs29*, in the iono-
tropic glutamate receptor, GluK1 (GRIK1), in a male who also carried a rare c.12232T>A, 
p.Lys411* GRIK1 variant (MAF= 0.00003314, ExAC Browser). DNA analysis was requested 
at the age of 62 due to trunk ataxia with dizziness, and low reflexes at a later age. To 
investigate the pathogenicity of both variants, we transiently transfected HEK293T cells 
with either wild type (WT) GluK1, GluK1-Glu841fs, or GluK1-Lys411*. Immunoblotting 
confirmed the presence of a shorter GluK1-Glu841fs protein compared to GluK1-WT, 
while no GluK1 protein was observed for GluK1-Lys411* (Supplementary Figure 1A). We 
hypothesize that GluK1-Lys411* is very likely unstable and gets degraded. Additionally, 
extracts of cells expressing GluK1-Glu841fs showed increased high molecular weight 
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species, indicative of altered solubility of the GluK1-Glu841fs receptor complexes 
(Supplementary Figure 1A). To investigate whether these mutant receptors can reach 
the cell surface, we performed immunocytochemistry on non-permeabilized SH-SY5Y 
cells expressing either GluK1-WT, GluK1-Glu841fs, or GluK1-Lys411*. GluK1-Glu841fs 
reached the cell surface (Supplementary Figure 1B), albeit less so than GluK1-WT 
(Supplementary Figure 1C). Whereas GluK1-Lys411* did not display surface expression 
(data not shown). We hypothesize that loss of one GRIK1 allele is benign, however, when 
both alleles generate modified or defective products, this leads to critically altered 
GluK1 complexes, inducing trunk ataxia. Whether the p.Glu841fs29* variation also af-
fects receptor functioning has not yet been determined.
Finally, we discovered a missense variation, c.3007C>T, p.Arg1003Trp (reported once in 
the ExAC browser), affecting a highly conserved amino acid, in the N-methyl-D-aspar-
tate receptor subunit GluN3B (GRIN3B) in a female who as a child was diagnosed with 
coordination problems, nystagmus, dystonic features, and intellectual disability. To in-
vestigate the consequences of the p.Arg1003Trp  variant, corresponding to p.Arg975Trp 
in rat Grin3b, we investigated the activity of receptor complexes including GluN1 and 
wild type or mutant GluN3B in Xenopus Oocytes. The p.Arg975Trp variant did not affect 
the glycine potency or Mg2+ block of recombinant GluN1/GluN3B receptors (Supple-
mentary Figure 2A and B), indicative of normal receptor activity. Furthermore, we inves-
tigated the cell surface expression of GluN1/GluN3B-WT and GluN1/GluN3B-Arg975Trp 
receptor complexes in HEK293T cells. Immunocytochemistry showed reduced cell 
surface expression of GluN1/GluN3B-Arg975Trp compared to GluN1/GluN3B-WT 
(Supplementary Figure 2C), which may be caused by impaired intracellular trafficking. 
Notably, benign null alleles of GRIN3B have been reported, but were not associated 
with motor neuron disease,10 suggesting that dominant negative mutations rather than 
haploinsufficiency of GRIN3B may lead to disease. Whether GluN3B-Arg975Trp exhibits 
dominant negative effects over GluN3B-WT remains unknown. 
In summary, we have identified the first mutations in GRIN3B and GRIK1 that link to 
ataxic phenotypes and/or intellectual disability. Two of the three cases in this work suf-
fer from both motor dysfunction and intellectual disability, suggesting that glutamate 
signaling may be a shared mechanism connecting these two disorders.  Addition-
ally, we postulate that regular SCA diagnostics are occasionally requested to exclude 
cerebellar ataxia rather than confirm it, and these patients could benefit from a more 
restricted clinical classification of this disorder. However, with the implementation of 
the disease-focused gene-panels, this problem will become less prominent in the 
future, as closely related disorders will be tested for simultaneously. Nevertheless, 
when ataxia or discoordination coincides with intellectual disability, neurologists and 
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clinical geneticists should consider screening a gene panel including genes coding for 
glutamatergic components.
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symbol Gene name HGNC
SN1 SLC38A3 solute carrier family 38, member 3 18044
EAAT SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 10941
  SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 10940
  SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, 
system Xag), member 1
10939
  SLC1A6 solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 10944
GLNT SLC38A1 solute carrier family 38, member 1 13447
  SLC38A2 solute carrier family 38, member 2 13448
mGluR GRM2 glutamate receptor, metabotropic 2 4594
  GRM3 glutamate receptor, metabotropic 3 4595
  GRM4 glutamate receptor, metabotropic 4 4596
  GRM5 glutamate receptor, metabotropic 5 4597
  GRM1 glutamate receptor, metabotropic 1 4593
  GRM7 glutamate receptor, metabotropic 7 4599
  GRM8 glutamate receptor, metabotropic 8 4600
GIRK KCNJ3 potassium channel, inwardly rectifying subfamily J, member 3 6264
KA GRIK1 glutamate receptor, ionotropic, kainate 1 4579
  GRIK2 glutamate receptor, ionotropic, kainate 2 4580
  GRIK3 glutamate receptor, ionotropic, kainate 3 4581
  GRIK4 glutamate receptor, ionotropic, kainate 4 4582
  GRIK5 glutamate receptor, ionotropic, kainate 5 4583
GLS GLS glutaminase 4331
  GLS2 glutaminase 2 (liver, mitochondrial) 29570
vGLUT SLC17A6 solute carrier family 17 (vesicular glutamate transporter), member 6 16703
  SLC17A7 solute carrier family 17 (vesicular glutamate transporter), member 7 16704
  SLC17A8 solute carrier family 17 (vesicular glutamate transporter), member 8 20151
AMPA GRIA1 glutamate receptor, ionotropic, AMPA 1 4571
  GRIA2 glutamate receptor, ionotropic, AMPA 2 4572
  GRIA3 glutamate receptor, ionotropic, AMPA 3 4573
  GRIA4 glutamate receptor, ionotropic, AMPA 4 4574
NMDAR GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 4584
  GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A 4585
  GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B 4586
  GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C 4587
  GRIN2D glutamate receptor, ionotropic, N-methyl D-aspartate 2D 4588
  GRIN3A glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 16767
  GRIN3B glutamate receptor, ionotropic, N-methyl-D-aspartate 3B 16768
TRPC1 TRPC1 transient receptor potential cation channel, subfamily C, member 1 12333
  TRPC3 transient receptor potential cation channel, subfamily C, member 3 12335














































Supplementary fi gure 1. GRIK1 variants aff ect protein expression
(A) Representative Western blot of HEK cells transfected with GluK1-WT-Myc, GluK1-Glu841fs29X-
Myc, or GluK1-Lys411*-Flag. GluK1-Glu841fs29X settled lower in the gel than GluK1-WT, indicating 
that this variant leads to a shorter GluK1 protein. GluK1-Lys411* protein was not detected on blots, 
indicating that this variant does not result in protein expression. (B-C) Representative micrographs 
of GluK1 receptor complexes in non-permeabilized SH-SY5Y cells expressing GluK1-WT-Myc or 
GluK1-Glu841fs-Myc. GluK1-Glu841fs receptor channels demonstrated surface expression, how-
ever, it was reduced as compared to GluK1-WT (B). GluK1-WT displayed robust surface expression 
(C). Scale bars, 25µm.
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Supplementary figure 2. GRIN3B-Arg1003Trp displays reduced surface expression
(A) Glycine response curve of rat GluN1/GluN3B and GluN1/GluN3B-Arg975Trp receptor channels 
as determined by two-electrode voltage-clamp recordings in Xenopus oocytes. The GluN1 subunit 
contained Phe484Ala and Thr518Lys mutations to prevent desensitization by eliminating glycine 
binding to GluN1 as previously described.11 GluN3B- Arg975Trp on the rat subunit corresponds to 
the human GluN3B- Arg1003Trp mutation. The GluN1/GluN3B- Arg975Trp channel did not show 
any changes as compared to GluN1/GluN3B channels. (B) The response to in the presence of 1 mM 
Mg2+ is shown as the percentage of the response in absence of Mg2+ (cells voltage-clamped at -80 
mV). The Grin3b- Arg975Trp variation did not alter the Mg2+ block of GluN1/GluN3B- Arg975Trp 
receptor channels compared to GluN1/GluN3B channels. (C) Surface expression of GluN1/GluN3B 
and GluN1/GluN3B- Arg975Trp receptor channels in transfected HEK cells. The Grin3b- Arg975Trp 
variation reduced surface expression by approximately 30% compared to wild type GluN1/GluN3B. 
* p < 0.05

